The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety of CC-97540 in ANCA-Associated Vasculitis
Timeframe: Study drug infusion (day 0) to 28 days post study drug infusion, assessed up to 12 months post study drug infusion.
Efficacy of CC-97540
Timeframe: Study drug infusion (day 0) to 28 days post study drug infusion, assessed up to 12 months post study drug infusion.